Evidence-based public policy making for medicines across countries: findings and implications for the future-Reference-Cited by-同舟云学术

Evidence-based public policy making for medicines across countries: findings and implications for the future

Published:2021-08 Issue:12 Volume:10 Page:1019-1052
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:Journal of Comparative Effectiveness Research

Author:

Godman Brian¹²³⁴^ORCID,Fadare Joseph⁵⁶^ORCID,Kwon Hye-Young⁷^ORCID,Dias Carolina Zampirolli⁸^ORCID,Kurdi Amanj¹³⁹^ORCID,Dias Godói Isabella Piassi¹⁰¹¹^ORCID,Kibuule Dan¹²^ORCID,Hoxha Iris¹³,Opanga Sylvia¹⁴,Saleem Zikria¹⁵^ORCID,Bochenek Tomasz¹⁶^ORCID,Marković-Peković Vanda¹⁷^ORCID,Mardare Ileana¹⁸^ORCID,Kalungia Aubrey C¹⁹^ORCID,Campbell Stephen²⁰²¹^ORCID,Allocati Eleonora²²,Pisana Alice²³,Martin Antony P²⁴^ORCID,Meyer Johanna C³^ORCID

Affiliation:

1. Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK

2. Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, SE-141 86, Stockholm, Sweden

3. School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa

4. School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia

5. Department of Pharmacology & Therapeutics, Ekiti State University, Ado-Ekiti, Nigeria

6. Department of Medicine, Ekiti State University Teaching Hospital, Ado-Ekiti, Nigeria

7. Division of Biology and Public Health, Mokwon University, Daejeon, Korea

8. Graduate Program in Public Health, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

9. Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq

10. Institute of Health & Biological Studies – Universidade Federal do Sul e Sudeste do Pará, Avenida dos Ipês, s/n, Cidade Universitária, Cidade Jardim, Marabá, Pará, Brazil

11. Researcher of the Group (CNPq) for Epidemiological, Economic and Pharmacological Studies of Arboviruses (EEPIFARBO) – Universidade Federal do Sul e Sudeste do Pará; Avenida dos Ipês, s/n, Cidade Universitária, Cidade Jardim, Marabá, Pará, Brazil

12. Department of Pharmacy Practice & Policy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia

13. Department of Pharmacy, Faculty of Medicine, University of Medicine Tirana, Albania

14. Department of Pharmaceutics & Pharmacy Practice, School of Pharmacy, University of Nairobi, Nairobi, Kenya

15. Faculty of Pharmacy, University of Lahore, Lahore, Pakistan

16. Department of Nutrition & Drug Research, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland

17. Department of Social Pharmacy, University of Banja Luka, Faculty of Medicine, Banja Luka, Republic of Srpska, Bosnia & Herzegovina

18. “Carol Davila” University of Medicine & Pharmacy, Bucharest, Romania

19. Department of Pharmacy, University of Zambia, Lusaka, Zambia

20. Centre for Primary Care, Division of Population Health, Health Services Research & Primary Care, University of Manchester, Manchester, M13 9PL, UK

21. NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UK

22. Istituto di Ricerche Farmacologiche ‘Mario Negri’ IRCCS, Milan, Italy

23. Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden

24. Faculty of Health & Life Sciences, The University of Liverpool, Brownlow Hill, Liverpool, L69 3BX, UK

Abstract

Aim: Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-communicable diseases (NCDs) and new premium priced medicines for cancer, orphan diseases and other complex areas. This is difficult to sustain without reforms. Methods: Extensive narrative review of published papers and contextualizing the findings to provide future guidance. Results: New models are being introduced to improve the managed entry of new medicines including managed entry agreements, fair pricing approaches and monitoring prescribing against agreed guidance. Multiple measures have also successfully been introduced to improve the prescribing of established medicines. This includes encouraging greater prescribing of generics and biosimilars versus originators and patented medicines in a class to conserve resources without compromising care. In addition, reducing inappropriate antibiotic utilization. Typically, multiple measures are the most effective. Conclusion: Multiple measures will be needed to attain and retain universal healthcare.

Publisher

Future Medicine Ltd

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer-2020-0273

Reference353 articles.

1. IQVIA. The Global Use of Medicine in 2019 and Outlook to 2023 - Forecasts and Areas to Watch (2019). www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023.pdf

2. OECD. Health at a Glance 2019: OECD INDICATORS. OECD Publishing, Paris (2019). https://doi.org/10.1787/4dd50c09-en

3. Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

4. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Charting the Etanercept Journey: Tracing Cost Dynamics in Poland’s Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly;BioDrugs;2024-06-11

2. Hospital prescribing patterns of antibiotics in Zambia using the WHO prescribing indicators post-COVID-19 pandemic: findings and implications;JAC-Antimicrobial Resistance;2023-12-28

3. A Narrative Review of Recent Antibiotic Prescribing Practices in Ambulatory Care in Tanzania: Findings and Implications;Medicina;2023-12-18

4. Coping with increasing medicine costs through greater adoption of generic prescribing and dispensing in Pakistan as an exemplar country;Expert Review of Pharmacoeconomics & Outcomes Research;2023-11-09

5. A Narrative Review of Antibiotic Prescribing Practices in Primary Care Settings in South Africa and Potential Ways Forward to Reduce Antimicrobial Resistance;Antibiotics;2023-10-14